Skip to main content

Table 1 Characteristics of healthy controls and HF patients

From: Impact of heart failure on the behavior of human neonatal stem cells in vitro

  Healthy control subjects (n = 12) Heart failure patients (n = 21)
Demographic data and medical history   
   Age [years] 40 (3, 24–71) 60 (12, 31–82)
   Sex (male/female) 6/6 (50%/50%) 15/6 (71%/29%)
   Smoking status 4 (25%) 9 (43%)
   HF duration [month] - 13 (4.6, 0.3-48)
   Previous surgery - 0
   Previous MI - 13 (62%)
   Time since most recent MI [month] - 2.7 (1.8, 0.1-36)
   Extent of CAD   
     One vessel - 0
     Two vessels - 0
     Three vessels - 21 (100%)
   NYHA functional class   
     III - 13 (62%)
     IV - 8 (38%)
   Heart rate [bpm] - 92 (13)
   Systolic blood pressure [mmHg] - 118 (26, 82–167)
   Diastolic blood pressure [mmHg] - 76 (19, 54–104)
Etiology   
   Ischemic - 16 (76%)
   Non-ischemic - 5 (24%)
   Idiopathic - 0
Echocardiographic data   
   LVEDD [mm] - 153 (38, 93–232)
   LVESD [mm] - 73 (26, 58–149)
   LVEF [%] - 24.7 (13.4, 15–38)
Surgery   
   Ventricular assist device - 5 (24%)
   Bypass graft - 12 (57%)
   Valve - 5 (24%)
Non-cardiac disease   
   Allergy 1 (8%) 4 (19%)
   S.p. apoplexia 1 (8%) 1 (5%)
   Hypertension 3 (25%) 17 (81%)
   Osteoporosis 1 (8%) 3 (14%)
   Hypothyroidism 2 (17%) 0
   Diabetes type II 1 (8%) 11 (52%)
   Chronic obstructive pulmonary disease 1 (8%) 3 (14%)
Pharmacological therapy   
   Aspirin 1 (8%) 12 (57%)
   Heparin 0 15 (71%)
   Coumadin 1 (8%) 3 (14%)
   Statins 1 (8%) 14 (67%)
   Loop diuretics 2 (17%) 15 (71%)
   β-blockers 1 (8%) 5 (24%)
   Digitoxin 0 8 (38%)
   Metformin 1 (8%) 0
   ACE Inhibitors 1 (8%) 17 (81%)
   Amniodarone 0 6 (29%)
   Amlodipine 1 (8%) 0
   Biphosphonates 1 (8%) 0
   Pantoprazole 0 18 (86%)
   Catecholamines 0 6 (29%)
  1. Data is expressed as number (percent) or as mean (SD, range).
  2. ABBREVIATIONS: MI myocardial infarction, CAD coronary artery disease, NYHA New York Heart Association, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVEF left ventricular ejection fraction.